Begin main content

Yervoy for advanced melanoma - Details

Project Number pCODR 10003
Brand Name Yervoy
Generic Name Ipilimumab
Strength 5 mg/mL
Tumour Type Skin and Melanoma
Indication Advanced Melanoma
Funding Request Treatment of advanced melanoma (unresectable Stage III and IV melanoma) in patients who have received prior systemic therapy
Review Status Notification to Implement Issued
Pre Noc Submission Yes
NOC Date February 1, 2012
Manufacturer Bristol-Myers Squibb Canada
Submitter Bristol-Myers Squibb Canada
Submission Date December 1, 2011
Submission Deemed Complete December 7, 2011
Submission Type New Drug
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ December 15, 2011
Check-point meeting January 24, 2012
pERC Meeting March 15, 2012
Initial Recommendation Issued March 29, 2012
Feedback Deadline ‡ April 16, 2012
Final Recommendation Issued April 18, 2012
Notification to Implement Issued May 2, 2012

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.